Chemicals · Founded 1992 · www.indoaminesltd.com · BSE 524648 · NSE INDO AMINES · ISIN INE760F01028
No Notes Added Yet
Business
Indo Amines Ltd. is an Indian manufacturer of specialty and fine chemicals. The company's core business involves the production of a diverse range of chemical intermediates, including various amines, nitriles, amides, and their derivatives. These products serve as essential building blocks and intermediates for a wide array of end-user industries, such as pharmaceuticals, agrochemicals, dyes & pigments, oil & gas, and other specialty chemical applications. The company generates revenue by manufacturing and supplying these specialized chemical products to domestic and international industrial clients.
Revenue Mix
Indo Amines operates primarily within the specialty chemicals segment. Its product portfolio can be broadly categorized into:
Aliphatic Amines & Derivatives
Aromatic Nitriles & Derivatives
Amides & Other Specialty Chemicals
Specific percentage contributions from each product category are not typically disclosed in detail in the company's publicly available investor materials. Revenue is generated from the sale of its entire suite of specialty chemical intermediates.
Industry
Indo Amines operates within the Indian specialty chemicals industry, a sector characterized by its fragmentation and significant growth potential. The company positions itself as a producer of niche and custom-synthesized chemicals, leveraging its process chemistry expertise. It competes with both larger, diversified chemical manufacturers and other specialized mid-sized players. Its broad product portfolio and presence across multiple end-user industries (pharma, agro, dyes) offer diversification within the specialty chemicals landscape.
MOAT
Product Diversification & Customization: A broad range of specialty chemical products coupled with the capability for custom synthesis helps create client stickiness.
Process Chemistry Expertise: Experience in handling complex chemical reactions and developing efficient processes for various intermediates.
Established Customer Relationships: Long-standing relationships with industrial clients in key end-user sectors, built on reliability and product quality.
In-house R&D: An R&D center focused on process optimization, new product development, and cost efficiency, which is vital for specialty chemical innovation.
Growth Drivers
Growth of End-User Industries: Continued expansion of the Indian pharmaceutical, agrochemical, and specialty dyes industries will drive sustained demand for chemical intermediates.
"China+1" Strategy: Global supply chain diversification away from China could lead to increased export opportunities for Indian specialty chemical manufacturers.
Import Substitution: Domestic focus on reducing reliance on imported chemicals, supported by government initiatives.
Capacity Expansion & New Product Development: Strategic capital expenditure to increase manufacturing capabilities and introduce new, higher-value molecules.
Enhanced R&D Focus: Investment in R&D to develop novel molecules and more sustainable manufacturing processes.
Risks
Raw Material Price Volatility: Dependence on commodity chemicals and crude oil derivatives makes the company susceptible to fluctuations in raw material prices, impacting margins.
Environmental & Regulatory Compliance: Stringent environmental regulations and escalating compliance costs pose operational and financial risks.
Intense Competition: The specialty chemicals sector is highly competitive, facing challenges from both domestic players and large international chemical companies.
Demand Fluctuations: Economic downturns or slowdowns in key client industries can adversely affect demand for specialty chemical products.
Foreign Exchange Risk: Exposure to foreign exchange rate fluctuations due to international raw material sourcing and product exports.
Management & Ownership
Indo Amines Ltd. is a promoter-driven company, with the Jhaveri family being the primary promoters. Mr. V.C. Jhaveri has been a key figure in the company's leadership. The promoter group holds a substantial equity stake (typically in the range of 65-67%), indicating strong ownership alignment with the company's performance. The management team has significant experience within the chemicals sector.
Outlook
Indo Amines Ltd. is positioned in the expanding Indian specialty chemicals market, which benefits from favorable trends such as the robust growth of its end-user industries (pharmaceuticals, agrochemicals), the global "China+1" supply chain diversification strategy, and domestic import substitution efforts. The company's diversified product portfolio, coupled with its R&D capabilities, provides a foundation for potential growth and resilience. However, the business is exposed to inherent risks including volatile raw material costs, intense competition, and the continuous need for investment in environmental compliance and capacity expansion. Future performance will largely depend on the effective management of these operational challenges, successful commercialization of new products, and efficient capital allocation in a dynamic chemical industry landscape.
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 253 | 265 | 269 | 259 | 285 | 288 | 277 | 277 | 318 | 375 |
| Other Income | 5 | 8 | 5 | 2 | 0 | 16 | 5 | 2 | 6 | 1 |
| Total Income | 258 | 273 | 275 | 261 | 286 | 303 | 282 | 280 | 324 | 376 |
| Total Expenditure | 236 | 237 | 245 | 234 | 261 | 256 | 245 | 252 | 283 | 322 |
| Operating Profit | 22 | 35 | 29 | 27 | 25 | 47 | 37 | 28 | 40 | 54 |
| Interest | 5 | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 6 | 6 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 13 | 26 | 19 | 17 | 15 | 36 | 26 | 16 | 29 | 42 |
| Provision for Tax | 3 | 6 | 6 | 5 | 3 | 7 | 7 | 4 | 8 | 11 |
| Profit After Tax | 9 | 19 | 14 | 11 | 12 | 29 | 18 | 12 | 21 | 31 |
| Adjustments | 0 | 0 | -0 | 0 | -0 | 0 | 0 | -0 | 0 | 0 |
| Profit After Adjustments | 9 | 19 | 14 | 11 | 12 | 29 | 18 | 12 | 21 | 31 |
| Adjusted Earnings Per Share | 1.3 | 2.7 | 1.9 | 1.6 | 1.6 | 4 | 2.5 | 1.6 | 2.8 | 4.2 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 253 | 286 | 355 | 528 | 479 | 541 | 786 | 945 | 944 | 1079 | 1160 | 1247 |
| Other Income | 1 | 5 | 4 | 7 | 7 | 8 | 10 | 4 | 16 | 15 | 29 | 14 |
| Total Income | 253 | 291 | 360 | 535 | 485 | 549 | 796 | 949 | 960 | 1094 | 1188 | 1262 |
| Total Expenditure | 222 | 250 | 315 | 473 | 437 | 479 | 734 | 858 | 864 | 978 | 1037 | 1102 |
| Operating Profit | 31 | 41 | 45 | 62 | 49 | 69 | 63 | 91 | 96 | 116 | 151 | 159 |
| Interest | 4 | 6 | 8 | 10 | 11 | 9 | 14 | 17 | 22 | 22 | 24 | 24 |
| Depreciation | 12 | 12 | 12 | 15 | 20 | 11 | 14 | 17 | 15 | 17 | 21 | 22 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 15 | 23 | 25 | 38 | 18 | 49 | 35 | 57 | 58 | 77 | 106 | 113 |
| Provision for Tax | 6 | 7 | 9 | 13 | 6 | 12 | 11 | 16 | 15 | 21 | 27 | 30 |
| Profit After Tax | 9 | 16 | 16 | 25 | 13 | 37 | 23 | 41 | 43 | 56 | 79 | 82 |
| Adjustments | 0 | 0 | 0 | -0 | -1 | 0 | -0 | -0 | -0 | -1 | -2 | 0 |
| Profit After Adjustments | 9 | 16 | 16 | 25 | 12 | 38 | 23 | 40 | 43 | 55 | 77 | 82 |
| Adjusted Earnings Per Share | 1.4 | 2.4 | 2.3 | 3.6 | 1.8 | 5.4 | 3.2 | 5.7 | 6 | 7.6 | 10.6 | 11.1 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 8% | 7% | 16% | 16% |
| Operating Profit CAGR | 30% | 18% | 17% | 17% |
| PAT CAGR | 41% | 24% | 16% | 24% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 3% | 6% | 4% | 17% |
| ROE Average | 22% | 20% | 18% | 20% |
| ROCE Average | 20% | 18% | 17% | 19% |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 50 | 69 | 81 | 125 | 135 | 163 | 187 | 225 | 263 | 317 | 392 |
| Minority's Interest | 0 | 0 | 0 | 0 | -1 | -0 | 0 | 0 | 0 | 1 | 1 |
| Borrowings | 14 | 14 | 19 | 26 | 36 | 53 | 51 | 58 | 60 | 79 | 85 |
| Other Non-Current Liabilities | -1 | -1 | 1 | 1 | 1 | -2 | 2 | 4 | 7 | 10 | 12 |
| Total Current Liabilities | 102 | 127 | 143 | 192 | 189 | 236 | 314 | 309 | 303 | 372 | 407 |
| Total Liabilities | 165 | 209 | 244 | 344 | 360 | 450 | 554 | 597 | 633 | 779 | 897 |
| Fixed Assets | 51 | 63 | 70 | 116 | 117 | 125 | 182 | 198 | 209 | 265 | 325 |
| Other Non-Current Assets | 1 | 44 | 15 | 20 | 31 | 61 | 32 | 27 | 29 | 50 | 43 |
| Total Current Assets | 112 | 102 | 159 | 209 | 211 | 265 | 340 | 373 | 395 | 464 | 530 |
| Total Assets | 165 | 209 | 244 | 344 | 360 | 450 | 554 | 597 | 633 | 779 | 897 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 6 | 6 | 5 | 8 | 10 | 10 | 15 | 24 | 18 | 21 | 15 |
| Cash Flow from Operating Activities | 19 | 15 | 8 | 27 | 39 | 56 | 15 | 20 | 70 | 35 | 79 |
| Cash Flow from Investing Activities | -10 | -23 | -21 | -43 | -36 | -50 | -39 | -30 | -27 | -82 | -71 |
| Cash Flow from Financing Activities | -9 | 7 | 16 | 17 | -3 | -1 | 32 | 4 | -41 | 42 | -1 |
| Net Cash Inflow / Outflow | 0 | -1 | 3 | 2 | 0 | 5 | 9 | -5 | 2 | -5 | 7 |
| Closing Cash & Cash Equivalent | 6 | 5 | 8 | 10 | 10 | 15 | 24 | 18 | 20 | 15 | 22 |
| # | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 1.38 | 2.42 | 2.34 | 3.55 | 1.81 | 5.35 | 3.23 | 5.72 | 6.03 | 7.61 | 10.59 |
| CEPS(Rs) | 3.22 | 4.23 | 4.18 | 5.64 | 4.57 | 6.88 | 5.25 | 8.23 | 8.21 | 10.05 | 13.89 |
| DPS(Rs) | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.55 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 |
| Book NAV/Share(Rs) | 7.59 | 10.37 | 11.91 | 17.47 | 18.88 | 22.83 | 26.32 | 31.68 | 37.22 | 43.65 | 54.03 |
| Core EBITDA Margin(%) | 10.57 | 11.16 | 10.01 | 8.89 | 6.93 | 9.19 | 4.78 | 6.57 | 6.04 | 6.9 | 7.66 |
| EBIT Margin(%) | 6.6 | 8.88 | 8.03 | 7.7 | 4.8 | 8.72 | 4.44 | 5.58 | 6.11 | 6.77 | 8.11 |
| Pre Tax Margin(%) | 5.16 | 7.08 | 6.08 | 6.12 | 3.02 | 7.34 | 3.16 | 4.28 | 4.42 | 5.25 | 6.62 |
| PAT Margin (%) | 3.19 | 5.02 | 3.85 | 4.06 | 2.11 | 5.61 | 2.11 | 3.08 | 3.26 | 3.81 | 4.95 |
| Cash Profit Margin (%) | 7.44 | 8.78 | 6.89 | 6.41 | 5.32 | 7.29 | 3.4 | 4.39 | 4.42 | 4.98 | 6.29 |
| ROA(%) | 5.68 | 8.63 | 6.88 | 8.58 | 3.64 | 9.26 | 4.59 | 7.1 | 6.96 | 7.92 | 9.46 |
| ROE(%) | 19.2 | 27.12 | 20.98 | 24.87 | 9.97 | 25.42 | 13.26 | 19.94 | 17.58 | 19.28 | 22.38 |
| ROCE(%) | 19.18 | 24.64 | 21.56 | 22.54 | 10.99 | 19.49 | 13.58 | 17.43 | 17.16 | 18.36 | 19.91 |
| Receivable days | 54.5 | 60.46 | 60.85 | 54.86 | 62.63 | 62.08 | 49.91 | 48.82 | 56.19 | 58.81 | 61.1 |
| Inventory Days | 34.48 | 33.99 | 38.47 | 34.69 | 44.32 | 46.36 | 35.19 | 35.56 | 34.66 | 31.62 | 36.24 |
| Payable days | 74.97 | 69.17 | 86.11 | 75.3 | 90.21 | 98.31 | 85.26 | 66.29 | 63.52 | 63.88 | 64.64 |
| PER(x) | 13.9 | 14.91 | 18.19 | 13.24 | 7.82 | 8.22 | 28.7 | 13.55 | 18.46 | 15.14 | 7.91 |
| Price/Book(x) | 2.53 | 3.48 | 3.57 | 2.69 | 0.75 | 1.93 | 3.52 | 2.45 | 2.99 | 2.64 | 1.55 |
| Dividend Yield(%) | 2.6 | 1.39 | 1.18 | 1.06 | 3.53 | 1.25 | 0.54 | 0.65 | 0.45 | 0.43 | 0.6 |
| EV/Net Sales(x) | 0.68 | 1.04 | 1.03 | 0.86 | 0.49 | 0.84 | 1.07 | 0.81 | 1.04 | 1.02 | 0.77 |
| EV/Core EBITDA(x) | 5.52 | 7.34 | 8.18 | 7.27 | 4.8 | 6.56 | 13.4 | 8.34 | 10.29 | 9.51 | 5.93 |
| Net Sales Growth(%) | 7.94 | 13.31 | 24.14 | 48.62 | -9.34 | 12.91 | 45.42 | 20.22 | -0.14 | 14.31 | 7.51 |
| EBIT Growth(%) | 39.57 | 51.85 | 13.86 | 47.18 | -38.96 | 99.37 | -16.7 | 52.67 | 8.48 | 23.59 | 30.83 |
| PAT Growth(%) | 73.22 | 77.54 | -3.45 | 61.87 | -49.22 | 192.49 | -38.51 | 77.36 | 4.74 | 30.56 | 41.92 |
| EPS Growth(%) | 73.22 | 75.24 | -3.45 | 52 | -48.98 | 195.31 | -39.69 | 77.21 | 5.32 | 26.28 | 39.25 |
| Debt/Equity(x) | 1.01 | 0.9 | 1.14 | 1.06 | 1.07 | 0.99 | 1.11 | 1.04 | 0.82 | 0.9 | 0.79 |
| Current Ratio(x) | 1.1 | 0.81 | 1.11 | 1.09 | 1.12 | 1.12 | 1.08 | 1.21 | 1.3 | 1.25 | 1.3 |
| Quick Ratio(x) | 0.84 | 0.54 | 0.75 | 0.74 | 0.69 | 0.75 | 0.69 | 0.77 | 0.93 | 0.87 | 0.86 |
| Interest Cover(x) | 4.59 | 4.93 | 4.12 | 4.87 | 2.69 | 6.31 | 3.47 | 4.29 | 3.61 | 4.45 | 5.47 |
| Total Debt/Mcap(x) | 0.4 | 0.26 | 0.32 | 0.42 | 1.51 | 0.51 | 0.32 | 0.42 | 0.28 | 0.34 | 0.51 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 66.76 | 66.76 | 57.25 | 57.25 | 58.37 | 58.42 | 58.42 | 58.42 | 58.42 | 58.42 |
| FII | 0.05 | 0 | 0.01 | 0.16 | 0.11 | 0.03 | 0 | 0 | 0.02 | 0.08 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 33.19 | 33.24 | 42.74 | 42.59 | 41.52 | 41.55 | 41.58 | 41.58 | 41.56 | 41.5 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 4.72 | 4.72 | 4.05 | 4.05 | 4.24 | 4.24 | 4.24 | 4.24 | 4.24 | 4.24 |
| FII | 0 | 0 | 0 | 0.01 | 0.01 | 0 | 0 | 0 | 0 | 0.01 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 2.35 | 2.35 | 3.02 | 3.01 | 3.01 | 3.02 | 3.02 | 3.02 | 3.02 | 3.01 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7.07 | 7.07 | 7.07 | 7.07 | 7.26 | 7.26 | 7.26 | 7.26 | 7.26 | 7.26 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +8% | +7% | +16% | +16% |
| Operating Profit CAGR | +30% | +18% | +17% | +17% |
| PAT CAGR | +41% | +24% | +16% | +24% |
| Share Price CAGR | +3% | +6% | +4% | +17% |
| ROE Average | +22% | +20% | +18% | +20% |
| ROCE Average | +20% | +18% | +17% | +19% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 66.76 | 66.76 | 57.25 | 57.25 | 58.37 | 58.42 | 58.42 | 58.42 | 58.42 | 58.42 |
| FII | 0.05 | 0 | 0.01 | 0.16 | 0.11 | 0.03 | 0 | 0 | 0.02 | 0.08 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 33.19 | 33.24 | 42.74 | 42.59 | 41.52 | 41.55 | 41.58 | 41.58 | 41.56 | 41.5 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 4.72 | 4.72 | 4.05 | 4.05 | 4.24 | 4.24 | 4.24 | 4.24 | 4.24 | 4.24 |
| FII | 0 | 0 | 0 | 0.01 | 0.01 | 0 | 0 | 0 | 0 | 0.01 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 2.35 | 2.35 | 3.02 | 3.01 | 3.01 | 3.02 | 3.02 | 3.02 | 3.02 | 3.01 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7.07 | 7.07 | 7.07 | 7.07 | 7.26 | 7.26 | 7.26 | 7.26 | 7.26 | 7.26 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.